ورود
مقالات فارسیISIکنفرانسهاژورنالها

Celecoxib inhibits acute edema and inflammatory biomarkers through peroxisome proliferator-activated receptor-γ in rats

محل انتشار: مجله علوم پایه پزشکی ایران، دوره: 23، شماره: 12
سال انتشار: 1399
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 245

فایل این مقاله در 7 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:
https://civilica.com/doc/1138550

شناسه ملی سند علمی:

JR_IJBMS-23-12_005

تاریخ نمایه سازی: 19 دی 1399

چکیده مقاله:

Objective(s): Celecoxib (CLX), a selective cyclooxygenase-II (COX-2) inhibitor, has been used for management of several inflammatory disorders. The present study aimed to explore the role of peroxisome proliferator-activated receptor-gamma (PPARγ) in CLX induced anti-inflammatory response in rats.Materials and Methods: Carrageenan-induced paw edema was used as an acute inflammation model. Rats were treated with various intra-peritoneal (IP) doses of CLX (0.3–30 mg/kg) and pioglitazone (PGL; PPARγ agonist, 1–20 mg/kg) alone or in combination. Amounts of PPARγ, COX-2, and prostaglandin E2 (PGE2) in paw tissue, and extents of TNF-α and IL-10 in serum were measured. Moreover, levels of oxidative stress parameters as malondialdehyde (MDA), glutathione (GSH), glutathione peroxidase (GPx) activity in the cortex, hippocampus, and paw tissues were also determined.  Results: CLX and PGL dose-dependent administration (IP), alone or in combination reduced carrageenan-induced paw edema. Further, both agents, alone or in combination, reduced either the amounts of COX-2, PGE2, and MDA in the inflamed paw, and the levels of TNF-α in serum which were elevated by carrageenan. Both drugs also increased both levels of PPARγ, GSH, GPx activity in paws, and serum levels of IL-10 that were decreased by carrageenan. Intraplantar injection of GW-9662 (IPL), a selective PPARγ antagonist, inhibited all biochemical modifications caused by both single and combined drug treatments. Conclusion: CLX produced its anti-inflammatory effects probably through PPARγ receptor activation. Besides, increased anti-inflammatory effects of CLX with PGL suggest that their combination might be applied for the clinical management of inflammation especially in patients suffering from diabetes.

کلیدواژه ها:

Carrageenan Celecoxib Cytokines Oxidative stress Pioglitazone PPAR ، γ Rat

نویسندگان

Gholamreza Houshmand

Department of Pharmacology, School of Medicine, Mazandaran University of Medical Sciences (MAZUMS), Sari, Iran

Bahareh Naghizadeh

Department of Anesthesiology, College of Physicians and Surgeons, Columbia University, New York, NY ۱۰۰۳۲, USA

Behnam Ghorbanzadeh

Department of Pharmacology, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran

Zahra Ghafouri

Department of Biochemistry Biophysics and Genetics, School of Medicine, Mazandaran University of Medical Sciences (MAZUMS), Sari, Iran

Mehdi Goudarzi

Medicinal Plant Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Mohammad taghi Mansouri

Department of Anesthesiology, College of Physicians and Surgeons, Columbia University, New York, NY ۱۰۰۳۲, USA

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • 1. Leonardi GC, Accardi G, Monastero R, Nicoletti F, Libra ...
  • 2. Stephenson J, Nutma E, van der Valk P, Amor ...
  • 3. Martinez BK, White CM. The emerging role of inflammation ...
  • 4. Xia C, Rao X, Zhong J. Role of T ...
  • 5. Gilligan JP, Lovato SJ, Erion MD, Jeng AY. Modulation ...
  • 6. Halici Z, Dengiz GO, Odabasoglu F, Suleyman H, Cadirci ...
  • 7. Adcock IM, Brown CR, Kwon O, Barnes PJ. Oxidative ...
  • 8. Ferrer MD, Busquets-Cortes C, Capo X, Tejada S, Tur ...
  • 9. Higuchi T, Takeuchi A, Munesue S, Yamamoto N, Hayashi ...
  • 10. Hiller JG, Sampurno S, Millen R, Kuruvilla N, Ho ...
  • 11. Wick M, Hurteau G, Dessev C, Chan D, Geraci ...
  • 12. Bermudez V, Finol F, Parra N, Parra M, Perez ...
  • 13. Lehrke M, Lazar MA. The many faces of PPAR ...
  • 14. El Dairi R, Huuskonen P, Pasanen M, Rysa J. ...
  • 15. Oliveira ACP, Bertollo CM, Rocha LTS, Nascimento EB, Costa ...
  • 16. Mansouri MT, Naghizadeh B, Ghorbanzadeh B, Rajabi H, Pashmforoush ...
  • 17. Vinegar R, Schreiber W, Hugo R. Biphasic development of ...
  • 18. Dudhgaonkar SP, Tandan SK, Bhat AS, Jadhav SH, Kumar ...
  • 19. Houshmand G, Mansouri MT, Naghizadeh B, Hemmati AA, Hashemitabar ...
  • 20. Napimoga MH, Souza GR, Cunha TM, Ferrari LF, Clemente-Napimoga ...
  • 21. Yamamoto A, Kakuta H, Sugimoto Y. Involvement of glucocorticoid ...
  • 22. Huang GJ, Pan CH, Wu CH. Sclareol exhibits anti-inflammatory ...
  • 23. Rahardjo B, Widjajanto E, Sujuti H, Keman K. Different ...
  • 24. Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson ...
  • 25. Malefyt RD, Abrams J, Bennett B, Figdor CG, Devries ...
  • 26. Nathan C. Points of control in inflammation. Nature 2002; ...
  • 27. Pinheiro RM, Calixto JB. Effect of the selective COX-2 ...
  • 28. Knopfova L, Smarda J. The use of COX-2 and ...
  • 29. Nacife VP, Soeiro MDC, Gomes RN, D’Avila H, Neto ...
  • 30. Ackerman WE, Zhang XLL, Rovin BH, Kniss DA. Modulation ...
  • 31. Linke B, Schreiber Y, Picard-Willems B, Slattery P, Nusing ...
  • 32. Kim SR, Lee KS, Park HS, Park SJ, Min ...
  • 33. Campisi J, Andersen JK, Kapahi P, Melov S. Cellular ...
  • 34. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation ...
  • 35. Keck T, Werner J, Banafsche R, Stalmann A, Schneider ...
  • 36. Malek A, Sager R, Schneider H. Effect of hypoxia, ...
  • 37. Salvemini D, Wang ZQ, Bourdon DM, Stern MK, Currie ...
  • 38. Amic A, Markovic Z, Markovic JMD, Jeremic S, Lucic ...
  • 39. Collino M, Aragno M, Mastrocola R, Gallichio M, Rosa ...
    • نمایش کامل مراجع